Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.

Rituximab improves interstitial lung disease associated with antisynthetase syndrome

10 Jun 2018

Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.

A total of 25 patients at the Brigham and Women’s Hospital (n=13) and University of Pittsburgh Medical Center (n=12) participated in the study. Antisynthetase antibodies (16 Jo1, six PL-12 and three PL-7) were identified in all patients. The main indication for RTX use in 21 patients (84 percent) was recurrent or progressive ILD due to the failure of other agents.

Comparisons between pre- and post-RTX pulmonary variables at 12 months showed stable or improved CT score and forced vital capacity in 88 percent and 79 percent of patients, respectively. Total lung capacity (%) increased from 56±13 to 64±13, and glucocorticoid dose decreased from 18±9 to 12±12 mg/day. Diffusing capacity of the lungs for carbon monoxide slightly decreased at 1 year, but it increased from 42±17 to 70±20 at 3 years.

Nonspecific interstitial pneumonia (NSIP; n=13) and usual interstitial pneumonia/fibrotic NSIP (n=5) were the most common imaging patterns on CT. Of these, five had concurrent elements of cryptogenic organizing pneumonia.

“RTX may play a therapeutic role in patients with antisynthetase syndrome (AS)-ILD, and further clinical investigation is warranted,” the authors said.

To evaluate clinical outcomes in patients with AS-ILD, the authors retrospectively identified all patients at two institutions who were treated with RTX and assessed baseline demographics, pulmonary function testing and chest CT pre- and post-RTX. Two radiologists independently evaluated CT using a standardized scoring system.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.